The study using FPD/AML-iPSCs further revealed the differential effect of heterozygous RUNX1 mutation in mice vs. human, where no thrombocytopenia was observed in mice whereas it caused defects in in vitro generation of megakaryocytes in human iPSCs. This evidence concerns the gene RUNX1 and acute myeloid leukemia.